PR Hub – Newsletter for November 21, 2010

Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl

Results Suggest Bardoxolone Methyl May Reduce the Stage of Disease and Improve Measures of Kidney Function in Patients with Chronic Kidney Disease and Type 2 Diabetes

IRVING, Texas and ABBOTT PARK, Illinois, November 20, 2010 – Reata Pharmaceuticals and Abbott (NYSE: ABT) today announced data from a
Phase 2b study which suggests that bardoxolone methyl, an … Read more »»».

Good News for Kidney Patients: World’s Largest Kidney Disease Trial Shows Big Benefits From Reducing Cholesterol

DENVER, November 20, 2010 – Around a quarter of all heart attacks, strokes, and operations to open
blocked arteries could be avoided in people with chronic kidney disease by
using the combination of ezetimibe and simvastatin to lower blood cholesterol
levels. That's the conclusion from the world's largest ever randomized trial
in kidney disease.

Unveiling … Read : Good News for Kidney Patients: World's Largest Kidney Disease Trial Shows Big Benefits From Reducing Cholesterol.